Highlight
1. Combining venetoclax with high-dose cytarabine and mitoxantrone (HAM) yields a complete remission or CR with incomplete hematologic recovery (CR/CRi) rate of 69% in relapsed/refractory acute myeloid leukemia (R/R AML) patients in a real-world setting.
2. The treatment regimen shows greater efficacy in patients with only one prior therapy line and those naïve to venetoclax.
3. One-year relapse-free survival (RFS) and overall survival (OS) rates are encouraging at 59% and 58%, respectively.
4. A prognostic model incorporating TP53 mutation, complex karyotype, multiple prior therapies, and poor performance status effectively stratifies patient outcomes, aiding individualized risk assessment.
